Cancer Research and Treatment

Original Article

Breast cancer

A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03): Dae-Won Lee, Bhumsuk Keam, Keun Seok Lee, Jin-Hee Ahn, Joohyuk Sohn, Jin Seok Ahn, Moon Hee Lee, Jee Hyun Kim, Kyung Eun Lee, Hyo Jung Kim, Si-Young Kim, Yeon Hee Park, Chan-Young Ock, Kyung-Hun Lee, Sae-Won Han, Sung-Bae Kim, Young Hyuck Im, Hyun Cheol Chung, Do-Youn Oh, Seock-Ah Im; Cancer Res Treat. 2023;55(2):523-530. Published online November 8, 2022; DOI: https://doi.org/10.4143/crt.2022.1360

Purpose
This single-arm phase II trial investigate the efficacy and safety of S-1 plus oxaliplatin (SOX) in patients with metastatic breast cancer.
Materials and Methods
Patients with metastatic breast cancer previously treated with anthracyclines and taxanes were enrolled. Patients received S-1 (40-60 mg depending on patient’s body surface area, twice a day, day 1-14) and oxaliplatin (130 mg/m2, day 1) in 3 weeks cycle until disease progression or unacceptable toxicity. The primary endpoint was objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumor 1.1. Secondary endpoints included time-to-progression (TTP), duration-of-response (DoR), overall survival (OS), and adverse events.
Results
A total of 87 patients were enrolled from 11 institutions in Korea. Hormone receptor was positive in 54 (62.1%) patients and six (6.9%) had human epidermal growth factor receptor 2–positive disease. Forty-eight patients (85.1%) had visceral metastasis and 74 (55.2%) had more than three sites of metastases. The ORR of SOX regimen was 38.5% (95% confidence interval [CI], 26.9 to 50.0) with a median TTP of 6.0 months (95% CI, 5.1 to 6.9). Median DoR and OS were 10.3 months (95% CI, 5.5 to 15.1) and 19.4 (95% CI, not estimated) months, respectively. Grade 3 or 4 neutropenia was reported in 28 patients (32.1%) and thrombocytopenia was observed in 23 patients (26.6%).
Conclusion
This phase II study showed that SOX regimen is a reasonable option in metastatic breast cancer previously treated with anthracyclines and taxanes.

Citations

Citations to this article as recorded by

Unraveling the immune landscape and therapeutic biomarker PMEPA1 for oxaliplatin resistance in colorectal cancer: A comprehensive approach
Zhengguang Zhang, Tianming Lu, Zhe Zhang, Zixian Liu, Ruoning Qian, Ruogu Qi, Fuqiong Zhou, Min Li
Biochemical Pharmacology.2024; 222: 116117. CrossRef
Efficacy and safety of utidelone plus capecitabine in advanced first-line therapy for metastatic breast cancer: A multicenter real-world study
Pingping Bi, Xi Wang, Rui Liu, Xiuqin Li, Shanrong Wei, Jiawen Zhao, Xin Tan, Fan Zhang, Qing Mao, Ying Zhang, Baoyan Tang, Xueqiong Xun, Rong Guo, Kai Zheng, Shaoqiang Zhou, Shicong Tang
Surgery Open Science.2023; 16: 171. CrossRef

5,062 View
173 Download
2 Web of Science
2 Crossref

Correspondence

Reply to Commentary on “A Nationwide Survey of Knowledge of and Compliance with Cancer Pain Management Guidelines by Korean Physicians”: Do Yeun Kim, Si-Young Kim; Cancer Res Treat. 2014;46(4):426-426. Published online July 31, 2014; DOI: https://doi.org/10.4143/crt.2014.123R

PDF PubReader ePub

8,699 View
61 Download

Original Articles

A Nationwide Survey of Knowledge of and Compliance with Cancer Pain Management Guidelines by Korean Physicians: Do Yeun Kim, Jin Seok Ahn, Kyung Hee Lee, Young Chul Kim, Juneyoung Lee, Si-Young Kim; Cancer Res Treat. 2014;46(2):131-140. Published online April 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.2.131

Abstract PDF PubReader ePub

Purpose

Although cancer pain is prevalent, under-treatment still remains a problem. Knowledge of and compliance with guidelines for management of cancer pain were analyzed for exploration of physician-related barriers to cancer pain management. In addition, physicians' knowledge and its correlation with cancer pain control were audited.

Materials and Methods

From July 8 to December 2, 2010, a nationwide survey of house staff enquired about their knowledge of cancer pain control guidelines, and the medical records of patients under their care were analyzed.

Results

In total, 180 physicians participated in the study. Their average score for knowledge was 14.6 (range, 7 to 19; maximum possible, 20). When the knowledge score was divided into low, medium, and high scores, patients receiving care from physicians with high levels of knowledge tended to have better cancer pain control (p<0.001). Of the total patients with severe pain, 19.5% were not prescribed strong opioids, and 40% were not prescribed any medication for breakthrough pain.

Conclusion

Physicians' knowledge of guidelines for control of cancer pain showed an association with improvement of pain management. Overall adherence to the guidelines was lacking. Continuous interventions such as education and audits regarding cancer pain control guidelines for physician are needed.

Citations

Citations to this article as recorded by

Physicians’ views of the use of morphine in palliative care: a cross-sectional survey from a tertiary care centre in Northern Sri Lanka
Balasingam Nisahan, Shobika Raviraj, Sancica Navaratnam, Rajeshkannan Nadarajah
BMC Research Notes.2025;[Epub] CrossRef
Compliance with the breakthrough cancer pain European guidelines and impact on patients' quality of life: an observational prospective study
Paolo Bossi, Tatiana Pietrzyńska, César Margarit Ferri, Irene Mansilla, Valeria Tellone, Sara Fioravanti, Giorgio Di Loreto, Alessandro Comandini
Frontiers in Pain Research.2024;[Epub] CrossRef
A Survey of Knowledge and Barriers of Healthcare Professionals toward Opioid Analgesics in Cancer Pain Management
Nehad M. Ayoub, Malak Jibreel, Khawla Nuseir, Ghaith M. Al-Taani, Manish Gupta
International Journal of Clinical Practice.2022; 2022: 1. CrossRef
Rapid-Onset Opioids for Management of Breakthrough Cancer Pain: Considerations for Daily Practice
Paolo Bossi, Yolanda Escobar, Federico Pea
Frontiers in Pain Research.2022;[Epub] CrossRef
Ozono y COVID-19: bases fisiológicas y sus posibilidades terapéuticas según el estadio evolutivo de la infección por SARS-Cov-2.
Marcos Edgar Fernández Cuadros, María Jesús Albaladejo Florin, Sandra Alava Rabasa, Daiana Peña Lora, Olga Susana Pérez Moro
Revista de la Sociedad Española del Dolor.2021;[Epub] CrossRef
Comparing Methadone Rotation to Consensus Opinion
Michael A. Smith, Kyle C. Quirk, D'Anna C. Saul, Phillip E. Rodgers, Maria J. Silveira
Journal of Pain and Symptom Management.2020; 59(1): 116. CrossRef
Physician’s Attitude toward Treating Breakthrough Cancer Pain in Korea
Min Seok Seo, Jae Yong Shim, Youn Seon Choi, Do Yeun Kim, In Gyu Hwang, Sun Kyung Baek, Jin Young Shin, Juneyoung Lee, Chang Geol Lee
The Korean Journal of Hospice and Palliative Care.2017; 20(1): 18. CrossRef
Commentary on “A Nationwide Survey of Knowledge of and Compliance with Cancer Pain Management Guidelines by Korean Physicians”
Kieran Walsh
Cancer Research and Treatment.2014; 46(4): 425. CrossRef

13,182 View
106 Download
7 Web of Science
8 Crossref

Combination of TRAP1 and ERCC1 Expression Predicts Clinical Outcomes in Metastatic Colorectal Cancer Treated with Oxaliplatin/5-Fluorouracil: Jae Joon Han, Sun Kyung Baek, Jae Jin Lee, Gou Young Kim, Si-Young Kim, Suk-Hwan Lee; Cancer Res Treat. 2014;46(1):55-64. Published online January 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.1.55

Abstract PDF PubReader ePub

PURPOSE
The novel heat shock protein tumor necrosis factor receptor-associated protein 1 (TRAP1) is associated with multidrug resistance in colorectal cancer (CRC) cells in vitro. Excision repair cross-complementation group 1 (ERCC1) expression levels in tumor tissues also predict clinical outcomes in metastatic CRC patients receiving combination oxaliplatin and 5-fluorouracil treatment. We investigated whether TRAP1 and ERCC1 protein expression by immunohistochemistry predict clinical outcomes in CRC patients.
MATERIALS AND METHODS
The study population consisted of 56 patients with metastatic CRC who received first-line oxaliplatin/5-fluorouracil therapy. Clinical response and overall survival (OS) by levels of the markers TRAP1 and ERCC1 were evaluated.
RESULTS
The rates of TRAP1 and ERCC1 expression were 21% and 52%, respectively. Patients negative for ERCC1 expression showed a tendency to respond to chemotherapy (p=0.066). Median OS was significantly longer in patients negative for TRAP1 than those positive for TRAP1 (p=0.023). Patients negative for ERCC1 expression also had a better OS than those positive for ERCC1 (p=0.021). The median OS was 30.9 months for patients negative for TRAP1 and ERCC1 compared to 13.2 months for those positive for TRAP1 and/or positive for ERCC1 expression (p=0.006). The combination of TRAP1 and ERCC1 expression was significantly associated with the response to chemotherapy (p=0.046) and independently predicted median OS in multivariate analysis (hazard ratio, 2.98; 95% confidence interval, 1.18 to 7.49).
CONCLUSION
The present study demonstrates that the combination of TRAP1 and ERCC1 expression predicts the survival of metastatic CRC patients who were treated with oxaliplatin/5-fluorouracil.

Citations

Citations to this article as recorded by

Mitochondria: a crucial factor in the progression and drug resistance of colorectal cancer
Ying Zhao, Xiaomin Guo, Li Zhang, Dongwei Wang, Yan Li
Frontiers in Immunology.2024;[Epub] CrossRef
New insights into molecular chaperone TRAP1 as a feasible target for future cancer treatments
Xiao-Tong Li, Ying-Shuang Li, Zhao-Yu Shi, Xiu-Li Guo
Life Sciences.2020; 254: 117737. CrossRef
Gene Copy Number and Post-Transductional Mechanisms Regulate TRAP1 Expression in Human Colorectal Carcinomas
Michele Pietrafesa, Francesca Maddalena, Luciana Possidente, Valentina Condelli, Pietro Zoppoli, Valeria Li Bergolis, Maria Grazia Rodriquenz, Michele Aieta, Giulia Vita, Franca Esposito, Matteo Landriscina
International Journal of Molecular Sciences.2019; 21(1): 145. CrossRef
HSPA1A, HSPA1L and TRAP1 heat shock genes may be associated with prognosis in ovarian epithelial cancer
Warne De Andrade, Let�cia Braga, Nikole Gon�ales, Luciana Silva, Agnaldo Da Silva Filho
Oncology Letters.2019;[Epub] CrossRef
Trps1 is associated with the multidrug resistance of lung cancer cell by regulating MGMT gene expression
Hongxiang Liu, Yi Liao, Meng Tang, Tao Wu, Deli Tan, Shixin Zhang, Haidong Wang
Cancer Medicine.2018; 7(5): 1921. CrossRef
Clinical importance of DNA repair in sporadic colorectal cancer
Gustavo A. Laporte, Natalia M. Leguisamo, Antonio N. Kalil, Jenifer Saffi
Critical Reviews in Oncology/Hematology.2018; 126: 168. CrossRef
Expression of DDB2 Protein in the Initiation, Progression, and Prognosis of Colorectal Cancer
Huaiwei Yang, Jingwei Liu, Jingjing Jing, Zeyang Wang, Yi Li, Kaihua Gou, Xue Feng, Yuan Yuan, Chengzhong Xing
Digestive Diseases and Sciences.2018; 63(11): 2959. CrossRef
Thymidylate synthase expression in primary colorectal cancer as a predictive marker for the response to 5‑fluorouracil‑ and oxaliplatin‑based preoperative chemotherapy for liver metastases
Hiroshi Takeyama, Tomoko Wakasa, Keisuke Inoue, Kotaro Kitani, Masanori Tsujie, Takafumi Ogawa, Masao Yukawa, Yoshio Ohta, Masatoshi Inoue
Molecular and Clinical Oncology.2018;[Epub] CrossRef
Clinicopathologic significance of TRAP1 expression in colorectal cancer: a large scale study of human colorectal adenocarcinoma tissues
Min Gyoung Pak, Hyong Jong Koh, Mee Sook Roh
Diagnostic Pathology.2017;[Epub] CrossRef
TRAP1: a viable therapeutic target for future cancer treatments?
Giacomo Lettini, Francesca Maddalena, Lorenza Sisinni, Valentina Condelli, Danilo Swann Matassa, Maria Paola Costi, Daniele Simoni, Franca Esposito, Matteo Landriscina
Expert Opinion on Therapeutic Targets.2017; 21(8): 805. CrossRef
TRAP1 protein signature predicts outcome in human metastatic colorectal carcinoma
Francesca Maddalena, Vittorio Simeon, Giulia Vita, Annamaria Bochicchio, Luciana Possidente, Lorenza Sisinni, Giacomo Lettini, Valentina Condelli, Danilo Swann Matassa, Valeria Li Bergolis, Alberto Fersini, Sante Romito, Michele Aieta, Antonio Ambrosi, Fr
Oncotarget.2017; 8(13): 21229. CrossRef
Nucleotide Excision Repair and Response and Survival to Chemotherapy in Colorectal Cancer Patients
Elisabeth J Kap, Odilia Popanda, Jenny Chang-Claude
Pharmacogenomics.2016; 17(7): 755. CrossRef
TRAP1 regulates cell cycle and apoptosis in thyroid carcinoma cells
Giuseppe Palladino, Tiziana Notarangelo, Giuseppe Pannone, Annamaria Piscazzi, Olga Lamacchia, Lorenza Sisinni, Girolamo Spagnoletti, Paolo Toti, Angela Santoro, Giovanni Storto, Pantaleo Bufo, Mauro Cignarelli, Franca Esposito, Matteo Landriscina
Endocrine-Related Cancer.2016; 23(9): 699. CrossRef
TRAP1 regulates stemness through Wnt/β-catenin pathway in human colorectal carcinoma
Giacomo Lettini, Lorenza Sisinni, Valentina Condelli, Danilo Swann Matassa, Vittorio Simeon, Francesca Maddalena, Marica Gemei, Elvira Lopes, Giulia Vita, Luigi Del Vecchio, Franca Esposito, Matteo Landriscina
Cell Death & Differentiation.2016; 23(11): 1792. CrossRef
TRAP1 downregulation in human ovarian cancer enhances invasion and epithelial–mesenchymal transition
Maria R Amoroso, Danilo S Matassa, Ilenia Agliarulo, Rosario Avolio, Haonan Lu, Lorenza Sisinni, Giacomo Lettini, Hani Gabra, Matteo Landriscina, Franca Esposito
Cell Death & Disease.2016; 7(12): e2522. CrossRef
A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites
Yan Zhang, Junli Ma, Sai Zhang, Ganlu Deng, Xiaoling Wu, Jingxuan He, Haiping Pei, Hong Shen, Shan Zeng
International Journal of Colorectal Disease.2015; 30(9): 1173. CrossRef
TRAP1 revisited: Novel localizations and functions of a ‘next-generation’ biomarker (Review)
MARIA ROSARIA AMOROSO, DANILO SWANN MATASSA, LORENZA SISINNI, GIACOMO LETTINI, MATTEO LANDRISCINA, FRANCA ESPOSITO
International Journal of Oncology.2014; 45(3): 969. CrossRef

12,582 View
104 Download
20 Web of Science
17 Crossref

A Randomized Double-Blind, Double-Dummy, Multicenter Trial of Azasetron versus Ondansetron to Evaluate Efficacy and Safety in the Prevention of Delayed Nausea and Vomiting Induced by Chemotherapy: Hee Yeon Lee, Hoon-Kyo Kim, Kyung Hee Lee, Bong-Seog Kim, Hong Suk Song, Sung Hyun Yang, Joon Hee Kim, Yeul Hong Kim, Jong Gwang Kim, Sang-We Kim, Dong-Wan Kim, Si-Young Kim, Hee Sook Park; Cancer Res Treat. 2014;46(1):19-26. Published online January 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.1.19

Abstract PDF PubReader ePub

PURPOSE
This study was conducted to evaluate the efficacy and safety of azasetron compared to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting.
MATERIALS AND METHODS
This study was a multi-center, prospective, randomized, double-dummy, double-blind and parallel-group trial involving 12 institutions in Korea between May 2005 and December 2005. A total of 265 patients with moderately and highly emetogenic chemotherapy were included and randomly assigned to either the azasetron or ondansetron group. All patients received azasetron (10 mg intravenously) and dexamethasone (20 mg intravenously) on day 1 and dexamethasone (4 mg orally every 12 hours) on days 2-4. The azasetron group received azasetron (10 mg orally) with placebo of ondansetron (orally every 12 hours), and the ondansetron group received ondansetron (8 mg orally every 12 hours) with placebo of azasetron (orally) on days 2-6.
RESULTS
Over days 2-6, the effective ratio of complete response in the azasetron and ondansetron groups was 45% and 54.5%, respectively (95% confidence interval, -21.4 to 2.5%). Thus, the non-inferiority of azasetron compared with ondansetron in delayed chemotherapy-induced nausea and vomiting was not proven in the present study. All treatments were well tolerated and no unexpected drug-related adverse events were reported. The most common adverse events related to the treatment were constipation and hiccups, and there were no differences in the overall incidence of adverse events.
CONCLUSION
In the present study, azasetron showed inferiority in the control of delayed chemotherapy-induced nausea and vomiting compared with ondansetron whereas safety profiles were similar between the two groups.

Citations

Citations to this article as recorded by

Influence of ABCB1 genetic polymorphisms on the antiemetic response to ondansetron-based medication for cisplatin-based chemotherapy in South Indian cancer patients in a tertiary care hospital
Ayyar Porkodi, Deepak Gopal Shewade, Goud Alladi Charanraj
Current Issues in Pharmacy and Medical Sciences.2023; 36(3): 129. CrossRef
Hiccups in Cancer Patients Receiving Chemotherapy: A Cross-Sectional Study
Mevlüde Ergen, Fatma Arikan, Rüya Fırat Çetin
Journal of Pain and Symptom Management.2021; 62(3): e85. CrossRef
A Fast and Validated HPLC Method for the Simultaneous Analysis of Five 5-HT3 Receptor Antagonists via the Quantitative Analysis of Multicomponents by a Single Marker
Fuchao Chen, Baoxia Fang, Peng Li, Sicen Wang, Amr M. Mahmoud
International Journal of Analytical Chemistry.2021; 2021: 1. CrossRef
Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis
Vanessa Piechotta, Anne Adams, Madhuri Haque, Benjamin Scheckel, Nina Kreuzberger, Ina Monsef, Karin Jordan, Kathrin Kuhr, Nicole Skoetz
Cochrane Database of Systematic Reviews.2021;[Epub] CrossRef
Effectiveness of Steroid Rotation in a Japanese Patient with Hiccups Caused by Dexamethasone: a Case Report
Hiroki Hosokawa, Hideaki Shimoda, Takayuki Ishii
YAKUGAKU ZASSHI.2019; 139(4): 647. CrossRef
Stability of azasetron-dexamethasone mixture for chemotherapy-induced nausea and vomiting administration
Bao-Xia Fang, Fu-Chao Chen, Dan Zhu, Jun Guo, Lin-Hai Wang
Oncotarget.2017; 8(63): 106249. CrossRef
Gender Differences in Hiccup Patients: Analysis of Published Case Reports and Case-Control Studies
Gyeong-Won Lee, Rock Bum Kim, Se Il Go, Hyun Seop Cho, Seung Jun Lee, David Hui, Eduardo Bruera, Jung Hun Kang
Journal of Pain and Symptom Management.2016; 51(2): 278. CrossRef
Cheaper Options in the Prevention of Chemotherapy-Induced Nausea and Vomiting
Bishal Gyawali, Bishesh Sharma Poudyal, Mahesh Iddawela
Journal of Global Oncology.2016; 2(3): 145. CrossRef
Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review
K. Jordan, F. Jahn, M. Aapro
Annals of Oncology.2015; 26(6): 1081. CrossRef

12,339 View
70 Download
8 Web of Science
9 Crossref

Preoperative Concurrent Chemoradiotherapy for Locally Advanced Rectal Cancer: Treatment Outcomes and Analysis of Prognostic Factors: Moonkyoo Kong, Seong Eon Hong, Woo Suk Choi, Si-Young Kim, Jinhyun Choi; Cancer Res Treat. 2012;44(2):104-112. Published online June 30, 2012; DOI: https://doi.org/10.4143/crt.2012.44.2.104

Abstract PDF PubReader ePub

PURPOSE
This study was designed to investigate the long-term oncologic outcomes for locally advanced rectal cancer patients after treatment with preoperative concurrent chemoradiotherapy followed by total mesorectal excision, and to identify prognostic factors that affect survival and pathologic response.
MATERIALS AND METHODS
From June 1996 to June 2009, 135 patients with locally advanced rectal cancer were treated with preoperative concurrent chemoradiotherapy followed by total mesorectal excision at Kyung Hee University Hospital. Patient data was retrospectively collected and analyzed in order to determine the treatment outcomes and identify prognostic factors for survival.
RESULTS
The median follow-up time was 50 months (range, 4.5 to 157.8 months). After preoperative chemoradiotherapy, sphincter preservation surgery was accomplished in 67.4% of whole patients. A complete pathologic response was achieved in 16% of patients. The estimated 5- and 8-year overall survival, loco-regional recurrence-free survival, and distant metastasis-free survival rate for all patients was 82.7% and 75.7%, 76.8% and 71.9%, 67.9% and 63.3%, respectively. The estimated 5- and 8-year overall survival, loco-regional recurrence-free survival, and distant metastasis-free survival rate for pathologic complete responders was 100% and 100%, 100% and 88.9%, 95.5% and 95.5%, respectively. In the multivariate analysis, pathologic complete response was significantly associated with overall survival. The predictive factor for pathologic complete response was pretreatment clinical stage.
CONCLUSION
Preoperative chemoradiotherapy for locally advanced rectal cancer resulted in a high rate of overall survival, sphincter preservation, down-staging, and pathologic complete response. The patients achieving pathologic complete response had very favorable outcomes. Pathologic complete response was a significant prognostic factor for overall survival and the significant predictive factor for a pathologic complete response was pretreatment clinical stage.

Citations

Citations to this article as recorded by

Analysis of clinical and pathological prognostic factors of survival in rectal adenocarcinoma treated with preoperative radiochemotherapy
Sarhan Sydney Saad, Nora Forones, Gaspar Lopes Filho, Jaques Waisberg, Elesiario Caetano Júnior, Ricardo Artigiani-Neto, Delcio Matos
Acta Cirúrgica Brasileira.2025;[Epub] CrossRef
The optimal time interval between neoadjuvant chemoradiotherapy and surgery for patients with an unfavorable pathological response in locally advanced rectal cancer: a retrospective cohort study
Litao Wang, Jianyong Fan, Yaqi Guo, Shipeng Shang, Han Gao, Jianfei Xu, Peng Gao, Enrui Liu
Frontiers in Oncology.2025;[Epub] CrossRef
Characteristics of Patients Presented With Metastases During or After Completion of Chemoradiation Therapy for Locally Advanced Rectal Cancer: A Case Series
Radwan Torky, Mohammed Alessa, Ho Seung Kim, Ahmed Sakr, Eman Zakarneh, Fozan Sauri, Heejin Bae, Nam Kyu Kim
Annals of Coloproctology.2021; 37(3): 186. CrossRef
A prospective analysis of the diagnostic accuracy of 3 T MRI, CT and endoscopic ultrasound for preoperative T staging of potentially resectable esophageal cancer
Jia Guo, Zhaoqi Wang, Jianjun Qin, Hongkai Zhang, Wentao Liu, Yan Zhao, Yanan Lu, Xu Yan, Zhongxian Zhang, Ting Zhang, Shouning Zhang, Nickel Marcel Dominik, Ihab R. Kamel, Hailiang Li, Jinrong Qu
Cancer Imaging.2020;[Epub] CrossRef
Sustaining Blood Lymphocyte Count during Preoperative Chemoradiotherapy as a Predictive Marker for Pathologic Complete Response in Locally Advanced Rectal Cancer
Jaesung Heo, Mison Chun, O Kyu Noh, Young-Taek Oh, Kwang Wook Suh, Jun Eun Park, Oyeon Cho
Cancer Research and Treatment.2016; 48(1): 232. CrossRef
Differential effects of patient-related factors on the outcome of radiation therapy for rectal cancer
Ikuko Kato, Gregory Dyson, Michael Snyder, Hyeong-Reh Kim, Richard K. Severson
Journal of Radiation Oncology.2016; 5(3): 279. CrossRef
JOURNAL CLUB: Preoperative MRI Evaluation of Primary Rectal Cancer: Intrasubject Comparison With and Without Rectal Distention
Feng Ye, Hongmei Zhang, Xiao Liang, Han Ouyang, Xinming Zhao, Chunwu Zhou
American Journal of Roentgenology.2016; 207(1): 32. CrossRef
Utility of high resolution MRI for pre-operative staging of rectal carcinoma, involvement of the mesorectal fascia and circumferential resection margin
Tamir A. Hassan, Hossam M. Abdel-Rahman, Hala Yehia Ali
The Egyptian Journal of Radiology and Nuclear Medicine.2016; 47(4): 1243. CrossRef
Severe weight loss during preoperative chemoradiotherapy compromises survival outcome for patients with locally advanced rectal cancer
Junzhong Lin, Jianhong Peng, Aiham Qdaisat, Liren Li, Gong Chen, Zhenhai Lu, Xiaojun Wu, Yuanhong Gao, Zhifan Zeng, Peirong Ding, Zhizhong Pan
Journal of Cancer Research and Clinical Oncology.2016; 142(12): 2551. CrossRef
Complete radiotherapy response in rectal cancer: A review of the evidence
Daniel G Couch
World Journal of Gastroenterology.2016; 22(2): 467. CrossRef
The Value of High-Resolution MRI Technique in Patients with Rectal Carcinoma: Pre-Operative Assessment of Mesorectal Fascia Involvement, Circumferential Resection Margin and Local Staging
Samah Kohla
Polish Journal of Radiology.2015; 80: 115. CrossRef
Is complete mesocolic excision with central vascular ligation safe and effective in the surgical treatment of right-sided colon cancers? A prospective study
Gennaro Galizia, Eva Lieto, Ferdinando De Vita, Francesca Ferraraccio, Anna Zamboli, Andrea Mabilia, Annamaria Auricchio, Paolo Castellano, Vincenzo Napolitano, Michele Orditura
International Journal of Colorectal Disease.2014; 29(1): 89. CrossRef
Accuracy of High-Resolution MRI with Lumen Distention in Rectal Cancer Staging and Circumferential Margin Involvement Prediction
Elsa Iannicelli, Sara Di Renzo, Mario Ferri, Emanuela Pilozzi, Marco Di Girolamo, Alessandra Sapori, Vincenzo Ziparo, Vincenzo David
Korean Journal of Radiology.2014; 15(1): 37. CrossRef
EURECCA colorectal: Multidisciplinary management: European consensus conference colon & rectum
Cornelis J.H. van de Velde, Petra G. Boelens, Josep M. Borras, Jan-Willem Coebergh, Andres Cervantes, Lennart Blomqvist, Regina G.H. Beets-Tan, Colette B.M. van den Broek, Gina Brown, Eric Van Cutsem, Eloy Espin, Karin Haustermans, Bengt Glimelius, Lene H
European Journal of Cancer.2014; 50(1): 1.e1. CrossRef
Eine intensivierte Chemotherapie erhöht die Effektivität nicht, oder doch?
Gunther Klautke
Info Onkologie.2014; 17(6): 17. CrossRef
Sphincter preservation in distal CT2N0 rectal cancer after preoperative chemoradiotherapy
Nir Wasserberg, Yulia Kundel, Ofer Purim, Andrei Keidar, Hanoch Kashtan, Eran Sadot, Eyal Fenig, Baruch Brenner
Radiation Oncology.2014;[Epub] CrossRef
Metformin use and improved response to therapy in rectal cancer
Heath D. Skinner, Christopher H. Crane, Christopher R. Garrett, Cathy Eng, George J. Chang, John M. Skibber, Miguel A. Rodriguez‐Bigas, Patrick Kelly, Vlad C. Sandulache, Marc E. Delclos, Sunil Krishnan, Prajnan Das
Cancer Medicine.2013; 2(1): 99. CrossRef

12,805 View
54 Download
17 Crossref

Case Report

A Case of Organizing Pneumonia Associated with Rituximab: Chi Hoon Maeng, Sang Ouk Chin, Byung Hyuk Yang, Si-young Kim, Hwi-Joong Youn, Kyung Sam Cho, Sun Kyung Baek, Sun Lee; Cancer Res Treat. 2007;39(2):88-91. Published online June 30, 2007; DOI: https://doi.org/10.4143/crt.2007.39.2.88

Abstract PDF PubReader ePub

Rituximab is a human/murine chimeric anti-CD20 monoclonal antibody used to treat CD20-positive B-cell non-Hodgkin's lymphoma (NHL). Although most of the adverse effects associated with rituximab are usually reversible and temporary infusion-related reactions, including fever, chills, flushing and skin reactions, there are several reports of pulmonary events after long-term administration of rituximab. We present a case of asymptomatic nodular organizing pneumonia occurring during rituximab-based chemotherapy in a patient with non-Hodgkin's lymphoma.

Citations

Citations to this article as recorded by

Ocrelizumab-associated cryptogenic organizing pneumonia in multiple sclerosis: Two case reports and comprehensive literature review
Alessandro Gans, Elena Pinuccia Verrengia, Elisabetta Ricchiuti, Serena Leva, Simona Brajkovic, Daniele Colombo, Antonino Mazzone, Alessandro Prelle
Multiple Sclerosis Journal.2024;[Epub] CrossRef
Rituximab for steroid-resistant organising pneumonia in a woman with rheumatoid arthritis
Christine Elizabeth Loftis, Emilia Dulgheru, Adolfo Kaplan
BMJ Case Reports.2022; 15(11): e249912. CrossRef
Organizing pneumonia associated with T‐cell lymphoma
Chrystal Chan, Andrei D. Fagarasanu, Andre Reid, Daniel C. Sadowski, Ashley‐Mae E. Gillson
Respirology Case Reports.2020;[Epub] CrossRef
Non-infectious pulmonary toxicity of rituximab: a systematic review
A. V. Hadjinicolaou, M. K. Nisar, H. Parfrey, E. R. Chilvers, A. J. K. Ostor
Rheumatology.2012; 51(4): 653. CrossRef
Toxic Epidermal Necrolysis after Rituximab Therapy for Immune Thrombocytopenic Purpura
Soo-Young Bae, Yeo-Kyeoung Kim, Joo-Young Yoon, Sung-Ji Lee, Dae Eun Kim, Sung Yoon Rew, Seung Dok Hong, Dae-Ho Jo, Joon-Il Hwang, Woo-Kyun Bae, Hyun-Jeong Shim, Jae-Sook Ahn, Deok-Hwan Yang, Sang-Hee Cho, Je-Jung Lee, Ik-Joo Chung, Hyeoung-Joon Kim
The Korean Journal of Hematology.2009; 44(2): 108. CrossRef

9,058 View
82 Download
5 Crossref

Original Articles

Effects of the Expression of Leptin and Leptin Receptor (OBR) on the Prognosis of Early-stage Breast Cancers: Yongnam Kim, Si-Young Kim, Jae Jin Lee, Jeongho Seo, Youn-Wha Kim, Suck Hwan Koh, Hwi-Joong Yoon, Kyung Sam Cho; Cancer Res Treat. 2006;38(3):126-132. Published online June 30, 2006; DOI: https://doi.org/10.4143/crt.2006.38.3.126

Abstract PDF PubReader ePub

Purpose

Obesity-related leptin and leptin receptor (OBR) have a relation to the development of cancer and metastasis and also the low survival rate for breast cancer patients. Leptin has been associated with increased aromatase activity and it displays functional cross-talk with estrogen. This study was designed to determine the relationship between the expression of leptin and OBR in breast cancer tissue and the prognosis of early-stage breast cancer patients, and especially for the tamoxifen-treated patients.

Materials and Methods

Ninety-five patients with early-stage breast cancer and who had undergone surgical treatment at Kyung Hee University Hospital between January 1994 and June 2004 were analyzed. The surgical specimens underwent immunohistochemical analysis for leptin and OBR. The patients' survival and clinical characteristics were obtained from the medical records.

Results

Of the 95 patients, 79 (83%) and 32 (33.7%) showed the expression of leptin and OBR in breast cancer tissue, respectively. The expression of leptin and OBR in breast cancer tissue was not significantly related to the clinicopathological characteristics, including obesity, the expression of hormonal receptor, the HER-2/neu expression, menopause, stage and the nuclear grade. The expression of leptin and OBR was not significantly related to the overall disease-free survival (DFS). For the tamoxifen-treated postmenopausal obese patients, the DFS of the leptin-positive group was higher than that of the leptin-negative group (p=0.017).

Conclusion

The expression of leptin and OBR in breast cancer tissue may be not a prognostic factor for disease-free survival of breast cancer patients. In the future, further studies are needed to determine whether leptin expression could be a predictive factor for tamoxifen therapy in the postmenopausal obese subgroup among the early breast cancer patients.

Citations

Citations to this article as recorded by

Exploring the multifaceted role of obesity in breast cancer progression
Sooraj Kakkat, Prabhat Suman, Elba A. Turbat- Herrera, Seema Singh, Debanjan Chakroborty, Chandrani Sarkar
Frontiers in Cell and Developmental Biology.2024;[Epub] CrossRef
Greater Body Fatness Is Associated With Higher Protein Expression of LEPR in Breast Tumor Tissues: A Cross-Sectional Analysis in the Women’s Circle of Health Study
Adana A.M. Llanos, John B. Aremu, Ting-Yuan David Cheng, Wenjin Chen, Marina A. Chekmareva, Elizabeth M. Cespedes Feliciano, Bo Qin, Yong Lin, Coral Omene, Thaer Khoury, Chi-Chen Hong, Song Yao, Christine B. Ambrosone, Elisa V. Bandera, Kitaw Demissie
Frontiers in Endocrinology.2022;[Epub] CrossRef
Association of Serum Leptin with Prognostic Factors in Breast Cancer
Amirreza Hajati, Farshad Talebian, Asrin Babahajian, Nasrin Daneshkhah, Bayazid Ghaderi
Sudan Journal of Medical Sciences.2022; 17(1): 4. CrossRef
Roles and mechanisms of adipokines in drug resistance of tumor cells
Yan Li, Chunyan Yu, Weimin Deng
European Journal of Pharmacology.2021; 899: 174019. CrossRef
Immunohistochemical analysis of adipokine and adipokine receptor expression in the breast tumor microenvironment: associations of lower leptin receptor expression with estrogen receptor-negative status and triple-negative subtype
Adana A. M. Llanos, Yong Lin, Wenjin Chen, Song Yao, Jorden Norin, Marina A. Chekmareva, Coral Omene, Lei Cong, Angela R. Omilian, Thaer Khoury, Chi-Chen Hong, Shridar Ganesan, David J. Foran, Michael Higgins, Christine B. Ambrosone, Elisa V. Bandera, Kit
Breast Cancer Research.2020;[Epub] CrossRef
Leptin signaling axis specifically associates with clinical prognosis and is multifunctional in regulating cancer progression
Tsung-Chieh Lin, Kuan-Wei Huang, Chia-Wei Liu, Yu-Chan Chang, Wei-Ming Lin, Tse-Yen Yang, Michael Hsiao
Oncotarget.2018; 9(24): 17210. CrossRef
Immunohistochemical staining of leptin is associated with grade, stage, lymph node involvement, recurrence, and hormone receptor phenotypes in breast cancer
Mohamad Nidal Khabaz, Amer Abdelrahman, Nadeem Butt, Lila Damnhory, Mohamed Elshal, Alia M. Aldahlawi, Swsan Ashoor, Basim Al-Maghrabi, Pauline Dobson, Barry Brown, Kaltoom Al-Sakkaf, Mohmmad Al-Qahtani, Jaudah Al-Maghrabi
BMC Women's Health.2017;[Epub] CrossRef
Leptin, adipocytes and breast cancer: Focus on inflammation and anti-tumor immunity
Laetitia Delort, Adrien Rossary, Marie-Chantal Farges, Marie-Paule Vasson, Florence Caldefie-Chézet
Life Sciences.2015; 140: 37. CrossRef
Leptine : implication dans la physiopathologie du cancer du sein
Florence Caldefie-Chézet, Virginie Dubois, Laetitia Delort, Adrien Rossary, Marie-Paule Vasson
Annales d'Endocrinologie.2013; 74(2): 90. CrossRef
Serum leptin level and waist-to-hip ratio (WHR) predict the overall survival of metastatic breast cancer (MBC) patients treated with aromatase inhibitors (AIs)
Mehmet Artac, Hakan Bozcuk, Aysel Kıyıcı, Orhan Onder Eren, Melih Cem Boruban, Mustafa Ozdogan
Breast Cancer.2013; 20(2): 174. CrossRef
Leptin attenuates the anti-estrogen effect of tamoxifen in breast cancer
Xiaofeng Chen, Xiaoming Zha, Wei Chen, Tingting Zhu, Jinrong Qiu, Oluf Dimitri Røe, Jun Li, Zhaoxia Wang, Yongmei Yin
Biomedicine & Pharmacotherapy.2013; 67(1): 22. CrossRef
The role of leptin receptor gene polymorphisms in determining the susceptibility and prognosis of NSCLC in Chinese patients
Yuliang Li, Jianli Geng, Yongzheng Wang, Qinghua Lu, Yimeng Du, Wujie Wang, Zheng Li
Journal of Cancer Research and Clinical Oncology.2012; 138(2): 311. CrossRef
Leptin and breast cancer: an overview
Mehmet Artac, Kadri Altundag
Medical Oncology.2012; 29(3): 1510. CrossRef

11,345 View
44 Download
13 Crossref

Increased ERCC Expression Correlates with Improved Outcome of Patients Treated with Cisplatin as an Adjuvant Therapy for Curatively Resected Gastric Cancer: Sun Kyung Baek, Si-Young Kim, Jae Jin Lee, Yoon Wha Kim, Hwi Joong Yoon, Kyung Sam Cho; Cancer Res Treat. 2006;38(1):19-24. Published online February 28, 2006; DOI: https://doi.org/10.4143/crt.2006.38.1.19

Abstract PDF PubReader ePub

Purpose

It has been reported that the overexpression of the excision repair cross-complementing 1 (ERCC1) gene, which is essential for the repair of cisplatin (CDDP)-DNA adducts, negatively influences the effectiveness of CDDP-based therapy for primary gastric cancer. We investigated whether the ERCC1 expression was associated with survival for gastric cancer patients in an adjuvant setting.

Materials and Methods

We retrospectively analyzed 44 patients who were diagnosed with stage II or higher disease after undergoing curative resection and they had also received cisplatin-based chemotherapy. The ERCC1 expression was examined by performing immunohistochemical (IHC) staining, and this was divided into two groups according to the percentage of IHC staining of the tumor cell nuclei (negative: 10% or less, positive: more than 10%).

Results

Among the 44 patients (ERCC1-negative/ERCC1-positive group=16/28), 32 patients were male and their median age was 52 years. There was no difference for the baseline characteristics of the two groups. The median follow-up duration was 41 months. The median disease-free survival (DFS) and the overall survival (OS) for the ERCC1-positive group were significant higher than those of the ERCC1-negative group (DFS: 40.4 vs. 14.6 months, p=0.02, OS: undefined vs. 20.4 months, p=0.008).

Conclusion

The overall survival in gastric cancer patients who received cisplatin-based adjuvant chemotherapy after a curative resection is higher in those patients showing the overexpression of the ERCC1 gene. However, prospective studies using the ERCC1 gene expression as a prognostic marker for the DNA repair activity are needed.

Citations

Citations to this article as recorded by

Somatic mutation of DNAH genes implicated higher chemotherapy response rate in gastric adenocarcinoma patients
Chunchao Zhu, Qin Yang, Jia Xu, Wenyi Zhao, Zizhen Zhang, Danhua Xu, Yeqian Zhang, Enhao Zhao, Gang Zhao
Journal of Translational Medicine.2019;[Epub] CrossRef
The design, analysis and application of mouse clinical trials in oncology drug development
Sheng Guo, Xiaoqian Jiang, Binchen Mao, Qi-Xiang Li
BMC Cancer.2019;[Epub] CrossRef
Methods and significance of the combined detection of HER2 gene amplification and chemosensitivity in gastric cancer
Yang-Kun Wang, Su-Nan Wang, Ying-Ying Li, Gong-Ping Wang, Tian Yun, Chao-Ya Zhu, Bin-Feng Yang, Cong-Yang Li, Bo Jiang, Mei-Ling Zhu
Cancer Biomarkers.2018; 21(2): 439. CrossRef
The Profile of Serum microRNAs Predicts Prognosis for Resected Gastric Cancer Patients Receiving Platinum-Based Chemotherapy
Jianning Song, Jie Yin, Zhigang Bai, Jun Zhang, Hua Meng, Jun Cai, Wei Deng, Xuemei Ma, Zhongtao Zhang
Digestive Diseases and Sciences.2017; 62(5): 1223. CrossRef
Haplotype analysis on relationship of ERCC2 and ERCC3 gene polymorphisms with osteosarcoma risk in Chinese young population
Qiang Xu, Zuofu Zhang, Weixue Sun, Baiqiang Hu
Mammalian Genome.2017; 28(5-6): 227. CrossRef
Prognostic value of excision repair cross-complementation group 1 expression in gastric cancer: A meta-analysis
PENG SONG, QIN YIN, MING LU, BO FU, BAOLIN WANG, QINGHONG ZHAO
Experimental and Therapeutic Medicine.2015; 9(4): 1393. CrossRef
Predictive value of excision repair cross-complementation group 1 expression for platinum-based chemotherapy and survival in gastric cancer: a meta-analysis
Anqi Yao, You Wang, Xiaohong Peng, Rong Ye, Qiaoli Wang, Yuexiao Qi, Fuxiang Zhou
Journal of Cancer Research and Clinical Oncology.2014; 140(12): 2107. CrossRef
Association between epidermal growth factor receptor gene copy number and ERCC1, BRCA1 protein expression in Chinese patients with non-small cell lung cancer
Yalei Zhang, Haihong Yang, Yuan Qiu, Qiuhua Deng, Jun Liu, Meiling Zhao, Ping He, Mingcong Mo, Xusen Zou, Jianxing He
Medical Oncology.2014;[Epub] CrossRef
The prognostic value of ERCC1 expression in gastric cancer patients treated with platinum-based chemotherapy: a meta-analysis
Kong-Kong Wei, Lei Jiang, Yao-Yao Wei, Yu-Feng Wang, Xuan-Kun Qian, Qiang Dai, Quan-Lin Guan
Tumor Biology.2014; 35(9): 8721. CrossRef
ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy
Sara De Dosso, Elena Zanellato, Martina Nucifora, Renzo Boldorini, Angelica Sonzogni, Roberto Biffi, Nicola Fazio, Eraldo Bucci, Ottavio Beretta, Stefano Crippa, Piercarlo Saletti, Milo Frattini
Cancer Chemotherapy and Pharmacology.2013; 72(1): 159. CrossRef
Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma
Malcolm H. Squires, Sarah B. Fisher, Kevin E. Fisher, Sameer H. Patel, David A. Kooby, Bassel F. El‐Rayes, Charles A. Staley, Alton B. Farris, Shishir K. Maithel
Cancer.2013; 119(17): 3242. CrossRef
GSTP1, ERCC1 and ERCC2 Polymorphisms, Expression and Clinical Outcome of Oxaliplatin-based Adjuvant Chemotherapy in Colorectal Cancer in Chinese Population
Hui-Yan Li, Xin Ge, Guang-Ming Huang, Kai-Yu Li, Jing-Quan Zhao, Xi-Miao Yu, Wen-Si Bi, Yu-Lin Wang
Asian Pacific Journal of Cancer Prevention.2012; 13(7): 3465. CrossRef
Association of Four ERCC1 and ERCC2 SNPs with Survival of Bone Tumour Patients
Ting Hao, Wei Feng, Jie Zhang, Yong-Jian Sun, Gang Wang
Asian Pacific Journal of Cancer Prevention.2012; 13(8): 3821. CrossRef
The Real Estate of Gastric Cancer Induction Therapy: Location Versus Intrinsic Molecular Architecture
Roderich E. Schwarz, John C. Mansour
Annals of Surgical Oncology.2012; 19(7): 2081. CrossRef
Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy
Ki Han Kim, Hyuk-Chan Kwon, Sung Yong Oh, Sung Hyun Kim, Suee Lee, Kyung A Kwon, Jin Seok Jang, Min Chan Kim, Su-Jin Kim, Hyo-Jin Kim
Biomarkers.2011; 16(1): 74. CrossRef
ERCC1: Impact in Multimodality Treatment of Upper Gastrointestinal Cancer
Ralf Metzger, Elfriede Bollschweiler, Arnulf H Hölscher, Ute Warnecke-Eberz
Future Oncology.2010; 6(11): 1735. CrossRef
Biomarker analysis in stage III–IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival
J-S Kim, M-A Kim, T M Kim, S-H Lee, D-W Kim, S-A Im, T-Y Kim, W H Kim, H-K Yang, D S Heo, Y-J Bang, K-U Lee, K-J Choe, N K Kim
British Journal of Cancer.2009; 100(5): 732. CrossRef

12,974 View
61 Download
17 Crossref

The Efficacy of a Modified Chronomodulated Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin in Advanced Colorectal Cancer (Preliminary Data): Ji Young Park, Si-Young Kim, Jae Jin Lee, Hwi Joong Yoon, Kyung Sam Cho; Cancer Res Treat. 2004;36(3):199-204. Published online June 30, 2004; DOI: https://doi.org/10.4143/crt.2004.36.3.199

Abstract PDF PubReader ePub

Purpose

To determine the efficacy and tolerability of a modified chronomodulated infusion of oxaliplatin, 5-fluorouracil (5-FU) and leucovorin in the treatment of advanced colorectal cancer.

Materials and Methods

Sixteen patients with relapsed or metastatic colorectal cancer were treated with an intravenous infusion of oxaliplatin 25 mg/m², 5-FU 700 mg/m² and leucovorin 20 mg/m² on days 1 to 5. The infusion of oxaliplatin was chronomodulated with a peak delivery rate at 16:00 p.m., with 5-FU infused constantly overnight. Each course was repeated every 21 days.

Results

The response rate was 38.5% (95% confidence interval [CI], 13.9% to 68.4%) in the 13 measurable patients, including 1 complete response (7.7%) and 4 partial responses (30.8%). Five patients (38.5%) had a stable disease and 3 (23.0%) a progressive disease. Three patients without a measurable lesion had improved status. The median time to progression and overall survival were 29 weeks and 85 weeks, respectively. Grade 3 thrombocytopenia occurred in 2.5% (2 cycles) and grade 3 vomiting in 12.5% (2 patients). Anorexia, stomatitis, diarrhea, pruritus, alopecia and peripheral neuropathy were mild and tolerable.

Conclusion

The modified chronomodulated infusion of oxaliplatin, 5-FU and leucovorin is effective and tolerable, but the number of patients was too small. Further study will be needed to confirm the efficacy of this regimen with a larger population of patients.

Citations

Citations to this article as recorded by

Combination Chemotherapy of Oxaliplatin, 5-Fluorouracil and Low Dose Leucovorin in Patients with Advanced Colorectal Cancer
Yoon Mi Shin, Hae Suk Han, Seong Woo Lim, Byung Chul Kim, Kyung Suck Cheoi, Young Ook Eum, Seung Taek Kim, Ki Hyeong Lee
Cancer Research and Treatment.2005; 37(5): 284. CrossRef

9,533 View
45 Download
1 Crossref

Editorial

Oxaliplatin: Is It a New Standard Weapon for Colorectal Cancer?: Si-Young Kim; Cancer Res Treat. 2004;36(2):91-92. Published online April 30, 2004; DOI: https://doi.org/10.4143/crt.2004.36.2.91

PDF PubReader ePub

Citations

Citations to this article as recorded by

Combination Chemotherapy of Oxaliplatin, 5-Fluorouracil and Low Dose Leucovorin in Patients with Advanced Colorectal Cancer
Yoon Mi Shin, Hae Suk Han, Seong Woo Lim, Byung Chul Kim, Kyung Suck Cheoi, Young Ook Eum, Seung Taek Kim, Ki Hyeong Lee
Cancer Research and Treatment.2005; 37(5): 284. CrossRef

6,900 View
41 Download
1 Crossref

Original Article

Randomized Phase III Trial of Cisplatin, Epirubicin, Leucovorin, 5-Fluorouracil (PELF) Combination versus 5-fluorouracil Alone as Adjuvant Chemotherapy in Curative Resected Stage III Gastric Cancer: Jae Jin Lee, Si-Young Kim, Im sik Shin, Kyung Sam Cho, Hoong-Zae Joo, Choong Yoon, Yoon Wha Kim, Hwi Joong Yoon; Cancer Res Treat. 2004;36(2):140-145. Published online April 30, 2004; DOI: https://doi.org/10.4143/crt.2004.36.2.140

Abstract PDF PubReader ePub

Purpose

The combination of cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) administration, as adjuvant chemotherapy after curative resection for gastirc cancer, was compared with 5-fluorouracil (5-FU) administration alone. This paper reports the results of a prospective randomized comparison of the two regimens, PELF and 5-FU.

Methods

From August 1996 to July 1999, 54 patients were selected subsequent to being diagnosed with stage III cancer after a curative resection for gastric cancer. The patients were stratified according to stage IIIA/IIIB and subtotal/total gastrectomy, and then they were randomized into each treatment group, i.e. the PELF or 5-FU alone groups.

Results

54 assessable patients were enrolled in this study: 28 received PELF and 26 received 5-FU alone. 12 patients relapsed in each group and the median follow-up duration was 42 months (range: 10~77 months). The overall survival rate and disease-free survival rate (DFS) were not significantly different between two groups, (5-year survival of PELF vs. 5-FU: 57% vs. 64%, 5-year DFS: 54% vs. 51%). The PELF combination was more toxic in terms of anemia, anorexia, nausea and diarrhea than the 5-FU.

Conclusions

This study showed that the PELF combination, as an adjuvant therapy for gastric cancer after a curative resection, was a less effective treatment, and it had more toxic effects than the 5-FU.

Citations

Citations to this article as recorded by

Multidisciplinary treatment strategy for locally advanced gastric cancer: A systematic review
Kotaro Sugawara, Yoshikuni Kawaguchi, Yasuyuki Seto, Jean-Nicolas Vauthey
Surgical Oncology.2021; 38: 101599. CrossRef
The Efficacy and Safety of (Neo)Adjuvant Therapy for Gastric Cancer: A Network Meta-analysis
Tom van den Ende, Emil ter Veer, Mélanie Machiels, Rosa M. A. Mali, Frank A. Abe Nijenhuis, Laura de Waal, Marety Laarman, Suzanne S. Gisbertz, Maarten C. C. M. Hulshof, Martijn G. H. van Oijen, Hanneke W. M. van Laarhoven
Cancers.2019; 11(1): 80. CrossRef
Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis
Tom van den Ende, Emil ter Veer, Rosa M. A. Mali, Mark I. van Berge Henegouwen, Maarten C. C. M. Hulshof, Martijn G. H. van Oijen, Hanneke W. M. van Laarhoven
Cancers.2019; 11(4): 530. CrossRef
COMplot, A Graphical Presentation of Complication Profiles and Adverse Effects for the Curative Treatment of Gastric Cancer: A Systematic Review and Meta-Analysis
Tom van den Ende, Frank A. Abe Nijenhuis, Héctor G. van den Boorn, Emil ter Veer, Maarten C. C. M. Hulshof, Suzanne S. Gisbertz, Martijn G. H. van Oijen, Hanneke W. M. van Laarhoven
Frontiers in Oncology.2019;[Epub] CrossRef
Comparative effectiveness of adjuvant treatments for resected gastric cancer: a network meta-analysis
Zhaolun Cai, Yiqiong Yin, Yuan Yin, Chaoyong Shen, Jian Wang, Xiaonan Yin, Zhixin Chen, Ye Zhou, Bo Zhang
Gastric Cancer.2018; 21(6): 1031. CrossRef
Current challenges of metastatic breast cancer
Bora Lim, Gabriel N. Hortobagyi
Cancer and Metastasis Reviews.2016; 35(4): 495. CrossRef
Management of Gastroesophageal Junction Tumors
Matthew P. Fox, Victor van Berkel
Surgical Clinics of North America.2012; 92(5): 1199. CrossRef

9,870 View
61 Download
7 Crossref

First
Prev
Page of 1
Next
Last

Search